PARIS, FRANCE / ACCESSWIRE / September 1, 2022 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
05.07.2022 - PARIS, FRANCE / ACCESSWIRE / July 5, 2022 / Pharnext SA (FR0011191287-ALPHA) (the Company ), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today .
DJ Pharnext: Findings on Symptoms Burden of Charcot-Marie-Tooth Disease Type 1A From the 'Real-World' Digital Lifestyle Study, CMT&Me, to be Presented at the ICNMD 2022 Pharnext Pharnext: Findings
Pharnext Holds Shareholders Meeting and Appoints Dr. James Kuo to Renewed Board of Directors - read this article along with other careers information, tips and advice on BioSpace